Radically altering drug discovery, designing globally important therapeutics

We design peptides with purpose – for globally important therapeutic applications

supt/page-header

Page Header

Unlocking novel chemical space to address challenging drug targets

supt/text-media

Text & Image

Our computational drug design platform connects and extracts insights from diverse biomedical data, allowing us to unlock a new universe of unexplored, novel peptides with powerful applications.

Introduce your section or article with a short text.

We generate novel compounds with an end-product and use in mind, focused toward unexplored intellectual property.

supt/introduction

Introduction

Discover our platform

supt/button

Button

Backed by leading life science &amp; technology investors

supt/section-partners

Partners

supt/list-partners

List of Partners

supt/card-partner

Card Partner

Europe and US-based life science &amp; technology fund

Leading international technology investment fund

Encourage your visitor to visit another page, to further understand/engage.

supt/section-ctas

Call-to-Actions

supt/list-ctas

List of Call-to-Actions

We enable novel peptide design, optimization and manufacturing across disease areas.

Platform Partnering

Partnering

supt/card-cta

Card Call-to-Action

Our internal, clinical-stage pipeline focuses solely on novel, highly potent, narrow and broad-spectrum anti-infectives for unmet needs.

Internal Assets

Pipeline

Latest news

See all news

supt/section-news

Latest News

Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021

Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics

Are you interested in working with Peptilogics on peptide drug discovery &amp; development?